Certara Agrees To Acquire Cheminformatics Software Provider Chemaxon; No Terms Disclosed

7/9/24 4:46:41 PM ET

Computer Software: Prepackaged Software

Technology

Get the next $CERT alert in real time by email

The transaction is expected to close in the second half of 2024, subject to regulatory approval and other customary closing conditions.

In 2024, Chemaxon is expected to generate software revenue greater than $20 million. Chemaxon has a revenue growth profile comparable to Certara's software business and is expected to reach an adjusted EBITDA margin near Certara's corporate average by the end of 2025.

Get the next $CERT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CERT

Date	Price Target	Rating	Analyst
9/27/2024	$16.00	Neutral → Buy	UBS
4/10/2024	$23.00	Sector Weight → Overweight	KeyBanc Capital Markets
4/4/2024		Mkt Perform	JMP Securities
2/26/2024	$19.00	Market Perform	Leerink Partners
12/7/2023	$17.00	Neutral	UBS
12/5/2023		Sector Weight	KeyBanc Capital Markets
8/22/2023	$24.50 → $17.00	Buy → Hold	Jefferies
8/10/2023		Outperform → Mkt Perform	William Blair

More analyst ratings

$CERT
Financials

Live finance-specific insights

Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences
RADNOR, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2024 after the market close on Wednesday, February 26th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. Certara also announced that company management will participate in the following investor conferences: Leerink Partners Global Healthcare ConferenceDate and Time: Tuesday
1/29/25 4:15:00 PM ET
$CERT
Computer Software: Prepackaged Software
Technology
Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results
Full-Year 2024 Revenue of $384.4 million, Bookings of $445.3 millionConfirms Adjusted EBITDA within Guidance Range of $120 million to $124 million RADNOR, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced revenue and bookings for the fourth quarter and full year of fiscal year 2024 based on a preliminary review of fourth quarter results. Preliminary financials for the fourth quarter of 2024 are expected to be as follows: Revenue of $99.7 million, compared to $88.0 million in the fourth quarter of 2023, representing growth of 13%. Software revenue of $41.6 million, compared to $33.6 million in th
1/15/25 7:55:00 AM ET
$CERT
Computer Software: Prepackaged Software
Technology
Certara Reports Third Quarter 2024 Financial Results
RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2024. Third Quarter Highlights: Revenue was $94.8 million, compared to $85.6 million in the third quarter of 2023, representing growth of 11%. Software revenue was $35.9 million, compared to $31.3 million in the third quarter of 2023, representing growth of 15%.Services revenue was $58.9 million, compared to $54.2 million in the third quarter of 2023, representing growth of 9%. Net loss was $1.4 million, compared to a net loss of $49.0 million in the third quarter of 2023. The $47.6 millio
11/6/24 4:15:00 PM ET
$CERT
Computer Software: Prepackaged Software
Technology

$CERT
Press Releases

Fastest customizable press release news feed in the world

Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences
RADNOR, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2024 after the market close on Wednesday, February 26th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. Certara also announced that company management will participate in the following investor conferences: Leerink Partners Global Healthcare ConferenceDate and Time: Tuesday
1/29/25 4:15:00 PM ET
$CERT
Computer Software: Prepackaged Software
Technology
Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results
Full-Year 2024 Revenue of $384.4 million, Bookings of $445.3 millionConfirms Adjusted EBITDA within Guidance Range of $120 million to $124 million RADNOR, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced revenue and bookings for the fourth quarter and full year of fiscal year 2024 based on a preliminary review of fourth quarter results. Preliminary financials for the fourth quarter of 2024 are expected to be as follows: Revenue of $99.7 million, compared to $88.0 million in the fourth quarter of 2023, representing growth of 13%. Software revenue of $41.6 million, compared to $33.6 million in th
1/15/25 7:55:00 AM ET
$CERT
Computer Software: Prepackaged Software
Technology
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
RADNOR, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that Company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Company management will present at 5:15PM PT on Wednesday, January 15th, 2025. A live webcast of the event will be available on Certara's investor relations website at https://ir.certara.com and will be available for replay for at least 30 days thereafter. About CertaraCertara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharm
1/2/25 4:15:00 PM ET
$CERT
Computer Software: Prepackaged Software
Technology

Certara Appoints John Reynders as New Independent Board Member
RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. "We are excited to welcome an accomplished pharmaceutical industry leader with a track record of success to Certara's Board," said William F. Feehery, PhD, CEO of Certara. "John's expertise in artificial intelligence, data science, and life science will provide immense value. We will draw on that expertise as we continue to develop and integrate transformational software and services that accelerate new medicines and increase the productivity of pharma R&
10/16/24 4:15:00 PM ET
$CERT
Computer Software: Prepackaged Software
Technology
MaxCyte Appoints Cynthia Collins to its Board of Directors
ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. "I am pleased to welcome Cynthia to MaxCyte's Board of Directors," said Mahe
10/15/24 8:05:00 AM ET
$CERT
$MXCT
$PSTX
Computer Software: Prepackaged Software
Technology
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Certara Appoints New Chief Human Resources Officer & General Counsel
RADNOR, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, has appointed Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel. "Rona and Daniel are leaders in their fields. They have proven track records of growing teams and building high-performing businesses," said William F. Feehery Ph.D., CEO, Certara. "I'm confident they will further Certara's mission of accelerating medicines to patients through the delivery of solutions that improve the entire drug research and development process." Ms. Anhalt will drive Certara's human capital management strategy. She will lead the company's global
5/21/24 8:00:00 AM ET
$CERT
Computer Software: Prepackaged Software
Technology

Certara Agrees To Acquire Cheminformatics Software Provider Chemaxon; No Terms Disclosed

Chat with this insight

Recent Analyst Ratings for
$CERT

$CERT
Financials

Live finance-specific insights

Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences

Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results

Certara Reports Third Quarter 2024 Financial Results

$CERT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Certara Inc.

Amendment: SEC Form SC 13G/A filed by Certara Inc.

SEC Form SC 13G/A filed by Certara Inc. (Amendment)

$CERT
Press Releases

Fastest customizable press release news feed in the world

Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences

Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results

Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

$CERT
Leadership Updates

Live Leadership Updates

Certara Appoints John Reynders as New Independent Board Member

MaxCyte Appoints Cynthia Collins to its Board of Directors

Certara Appoints New Chief Human Resources Officer & General Counsel

$CERT
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Certara Inc.

Certara Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Amendment: SEC Form 10-K/A filed by Certara Inc.

$CERT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Certara upgraded by UBS with a new price target

Certara upgraded by KeyBanc Capital Markets with a new price target

JMP Securities initiated coverage on Certara

$CERT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Reynders John V W

SEC Form 3 filed by new insider Reynders John V W

PRESIDENT, DRUG DEV SOLUTIONS Smith Patrick F sold $59,661 worth of shares (5,409 units at $11.03), decreasing direct ownership by 10% to 50,091 units (SEC Form 4)

Certara Agrees To Acquire Cheminformatics Software Provider Chemaxon; No Terms Disclosed

Chat with this insight

Recent Analyst Ratings for $CERT

$CERT Financials

Live finance-specific insights

Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences

Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results

Certara Reports Third Quarter 2024 Financial Results

$CERT Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Certara Inc.

Amendment: SEC Form SC 13G/A filed by Certara Inc.

SEC Form SC 13G/A filed by Certara Inc. (Amendment)

$CERT Press Releases

Fastest customizable press release news feed in the world

Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences

Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results

Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

$CERT Leadership Updates

Live Leadership Updates

Certara Appoints John Reynders as New Independent Board Member

MaxCyte Appoints Cynthia Collins to its Board of Directors

Certara Appoints New Chief Human Resources Officer & General Counsel

$CERT SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Certara Inc.

Certara Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Amendment: SEC Form 10-K/A filed by Certara Inc.

$CERT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Certara upgraded by UBS with a new price target

Certara upgraded by KeyBanc Capital Markets with a new price target

JMP Securities initiated coverage on Certara

$CERT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Reynders John V W

SEC Form 3 filed by new insider Reynders John V W

PRESIDENT, DRUG DEV SOLUTIONS Smith Patrick F sold $59,661 worth of shares (5,409 units at $11.03), decreasing direct ownership by 10% to 50,091 units (SEC Form 4)

Recent Analyst Ratings for
$CERT

$CERT
Financials

$CERT
Large Ownership Changes

$CERT
Press Releases

$CERT
Leadership Updates

$CERT
SEC Filings

$CERT
Analyst Ratings

$CERT
Insider Trading